"Vidarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
| Descriptor ID |
D014740
|
| MeSH Number(s) |
D03.633.100.759.590.138.900 D13.570.065.950 D13.570.583.138.900
|
| Concept/Terms |
Vidarabine- Vidarabine
- beta-Ara A
- beta Ara A
- Adenine Arabinoside
- Arabinoside, Adenine
- alpha-D-Arabinofuranosyladenine
- alpha D Arabinofuranosyladenine
- Ara A
- alpha-Ara A
- alpha Ara A
- Arabinofuranosyladenine
- Arabinosyladenine
- 9-beta-D-Arabinofuranosyladenine
- 9 beta D Arabinofuranosyladenine
- 9-beta-Arabinofuranosyladenine
- 9 beta Arabinofuranosyladenine
- Ara-A
|
Below are MeSH descriptors whose meaning is more general than "Vidarabine".
Below are MeSH descriptors whose meaning is more specific than "Vidarabine".
This graph shows the total number of publications written about "Vidarabine" by people in this website by year, and whether "Vidarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 2000 | 3 | 1 | 4 |
| 2001 | 0 | 2 | 2 |
| 2002 | 2 | 2 | 4 |
| 2003 | 3 | 0 | 3 |
| 2004 | 4 | 0 | 4 |
| 2005 | 0 | 3 | 3 |
| 2007 | 1 | 2 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 5 | 7 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 3 | 6 |
| 2017 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vidarabine" by people in Profiles.
-
High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT). Eur J Haematol. 2024 Jul; 113(1):110-116.
-
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? Leuk Lymphoma. 2020 07; 61(7):1529-1534.
-
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
-
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv. 2018 06 12; 2(11):1198-1206.
-
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer. 2017 03 16; 17(1):198.
-
The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation. 2017 Jan; 101(1):e34-e38.
-
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 08; 22(8):1424-1430.
-
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75.
-
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61.
-
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):694-8.